Sirolimus Plus MEC Chemotherapy Has Significant Activity in High Risk AML Patients Especially Those Who Exhibit in Vivo Inhibition of the mTOR Pathway
| Autor: | Kasner, Margaret, Weiss, Mark, Flomenberg, Neal, Luger, Selina M., Loren, Alison W., Carabasi, Matthew, Wagner, John L. *, Mangan, James K., Frey, Noelle V., Filicko-O'Hara, Joanne, Besa, Emmanuel C., Hexner, Elizabeth O., Porter, David L, Gitelson, Elena, Martinez-Outschoorn, Ubaldo, Alpdogan, Onder, Grosso, Dolores *, Jeschke, Grace R *, Mick, Rosemarie *, Babcock, Patricia *, Hess, Rosemary *, Coffan, Kristin *, Cannon, B Joy *, DiMeglio, Martina *, Carroll, Martin, Perl, Alexander E |
|---|---|
| Zdroj: | In Blood 16 November 2012 120(21):143-143 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|